
Novel NLRP3 ингибитор, reducing caspase-1 activation, oligomerization of ASC, and therefore, IL-1β processing, showing a significant anti-inflammatory effect and reduced mechanical hyperalgesia at 3 and 10 mg/kg (i.p.) in an in vivo mouse of gout
Novel NLRP3 inhibitor, reducing caspase-1 activation, oligomerization of ASC, and therefore, IL-1β processing, showing a significant anti-inflammatory effect and reduced mechanical hyperalgesia at 3 and 10 mg/kg (i.p.) in an in vivo mouse of gout
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.